CN117904066A - Recombinant carbonyl reductase mutant and application thereof in catalytic synthesis of chiral alcohol - Google Patents
Recombinant carbonyl reductase mutant and application thereof in catalytic synthesis of chiral alcohol Download PDFInfo
- Publication number
- CN117904066A CN117904066A CN202410092889.4A CN202410092889A CN117904066A CN 117904066 A CN117904066 A CN 117904066A CN 202410092889 A CN202410092889 A CN 202410092889A CN 117904066 A CN117904066 A CN 117904066A
- Authority
- CN
- China
- Prior art keywords
- carbonyl reductase
- recombinant
- mutant
- substrate
- recombinant carbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010031132 Alcohol Oxidoreductases Proteins 0.000 title claims abstract description 76
- 102000005751 Alcohol Oxidoreductases Human genes 0.000 title claims abstract description 76
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 17
- 238000007036 catalytic synthesis reaction Methods 0.000 title description 3
- 102000004190 Enzymes Human genes 0.000 claims abstract description 55
- 108090000790 Enzymes Proteins 0.000 claims abstract description 55
- 239000000758 substrate Substances 0.000 claims abstract description 51
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims abstract description 44
- 238000006243 chemical reaction Methods 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 29
- 150000002576 ketones Chemical class 0.000 claims abstract description 13
- 239000002243 precursor Substances 0.000 claims abstract description 12
- 150000001413 amino acids Chemical group 0.000 claims abstract description 9
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 6
- 235000003704 aspartic acid Nutrition 0.000 claims abstract description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 241000221523 Rhodotorula toruloides Species 0.000 claims abstract description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000004473 Threonine Substances 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 28
- 230000035772 mutation Effects 0.000 claims description 14
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 14
- 241000894006 Bacteria Species 0.000 claims description 12
- 239000003054 catalyst Substances 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 8
- 241001052560 Thallis Species 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 238000010353 genetic engineering Methods 0.000 claims description 5
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 238000006722 reduction reaction Methods 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 abstract description 27
- 238000006555 catalytic reaction Methods 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 18
- 239000005515 coenzyme Substances 0.000 abstract description 17
- 230000008929 regeneration Effects 0.000 abstract description 8
- 238000011069 regeneration method Methods 0.000 abstract description 8
- 238000003786 synthesis reaction Methods 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 230000008878 coupling Effects 0.000 abstract description 4
- 238000010168 coupling process Methods 0.000 abstract description 4
- 238000005859 coupling reaction Methods 0.000 abstract description 4
- 238000010531 catalytic reduction reaction Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 27
- 239000000243 solution Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- 241000588724 Escherichia coli Species 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 12
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 11
- 235000011130 ammonium sulphate Nutrition 0.000 description 10
- 239000011942 biocatalyst Substances 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 101150097393 SCR gene Proteins 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 239000008057 potassium phosphate buffer Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000007853 buffer solution Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 238000005185 salting out Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 102000009105 Short Chain Dehydrogenase-Reductases Human genes 0.000 description 5
- 108010048287 Short Chain Dehydrogenase-Reductases Proteins 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000003760 magnetic stirring Methods 0.000 description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000186660 Lactobacillus Species 0.000 description 4
- -1 aldehyde esters Chemical class 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 3
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229910052755 nonmetal Inorganic materials 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 229920002271 DEAE-Sepharose Polymers 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- FESAXEDIWWXCNG-UHFFFAOYSA-N diethyl(methoxy)borane Chemical compound CCB(CC)OC FESAXEDIWWXCNG-UHFFFAOYSA-N 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000006920 protein precipitation Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- HZFVMVGCJSJLHT-UHNVWZDZSA-N (3r,5s)-6-chloro-3,5-dihydroxyhexanoic acid Chemical compound ClC[C@@H](O)C[C@@H](O)CC(O)=O HZFVMVGCJSJLHT-UHNVWZDZSA-N 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 108010084469 Aldo-Keto Reductases Proteins 0.000 description 1
- 102000005602 Aldo-Keto Reductases Human genes 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- ZUYPZFBFGJUZNA-JTQLQIEISA-N C(#N)C[C@@H](CC(CC(=O)OC(C)(C)C)=C=O)O Chemical compound C(#N)C[C@@H](CC(CC(=O)OC(C)(C)C)=C=O)O ZUYPZFBFGJUZNA-JTQLQIEISA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241001259751 Candida theae Species 0.000 description 1
- SUTLEVKHNODETR-VIFPVBQESA-N ClC[C@H](CC(CC(=O)OC(C)(C)C)=C=O)O Chemical compound ClC[C@H](CC(CC(=O)OC(C)(C)C)=C=O)O SUTLEVKHNODETR-VIFPVBQESA-N 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 108010025076 Holoenzymes Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- 101001110310 Lentilactobacillus kefiri NADP-dependent (R)-specific alcohol dehydrogenase Proteins 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 241000233540 Novosphingobium aromaticivorans Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 241001278052 Starmerella Species 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000008040 ionic compounds Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- FIKPWJZUGTVXCO-SFYZADRCSA-N tert-butyl (3r,5s)-6-chloro-3,5-dihydroxyhexanoate Chemical compound CC(C)(C)OC(=O)C[C@H](O)C[C@H](O)CCl FIKPWJZUGTVXCO-SFYZADRCSA-N 0.000 description 1
- WLRFCPQXWBDLRG-QMMMGPOBSA-N tert-butyl (5s)-6-chloro-5-hydroxy-3-oxohexanoate Chemical compound CC(C)(C)OC(=O)CC(=O)C[C@H](O)CCl WLRFCPQXWBDLRG-QMMMGPOBSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/002—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by oxidation/reduction reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/62—Carboxylic acid esters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01184—Carbonyl reductase (NADPH) (1.1.1.184)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The invention provides a recombinant carbonyl reductase mutant, which is obtained by mutating aspartic acid at the 25 th position of an amino acid sequence of Rhodosporidium toruloides ZJB 2014212-derived recombinant carbonyl reductase into threonine. The recombinant carbonyl reductase mutant has high activity and high stereoselectivity compared with wild enzyme, and further improves the catalysis efficiency of substrate precursor ketone. The recombinant carbonyl reductase mutant is applied to the synthesis of chiral alcohol by a biological enzyme method, and asymmetric catalytic reduction is carried out on substrate precursor ketone, so that compared with the wild type enzyme, the catalytic activity is improved during the reaction, and the time consumption of the reaction process is shortened. In addition, in the reaction system for preparing chiral alcohol by catalysis, a single-enzyme double-substrate coupling system is constructed, isopropanol is selected as an auxiliary substrate of a coenzyme regeneration system, so that the production cost can be effectively saved, and the method has important significance for industrial application of preparing chiral alcohol by catalysis of a biological enzyme method.
Description
Technical Field
The invention belongs to the field of bioconversion, and particularly relates to a recombinant carbonyl reductase mutant and application thereof in catalytic synthesis of chiral alcohol.
Background
Carbonyl reductases are a class of enzymes that undergo reversible redox reactions, with the co-enzyme NADP (H) or NAD (H) being the hydrogen mediator involved in catalyzing aldehydes/ketones with alcohols, and are considered to be one of the most commonly used biocatalysts in the synthesis of chiral alcohols. Carbonyl reductases are widely available and are commonly found in natural environments such as various plant, bacterial, fungal and animal tissues. Carbonyl reductase is mainly distributed in 3 superfamilies of short-chain dehydrogenase (short-chain Dehydrogenase, SDRs), aldehyde-ketone reductase (aldo-ketoreductases, AKRs), medium-chain dehydrogenase (medium-chain dehydrogenases, MDRs), which all catalyze similar reactions, although they differ greatly in steric structure, catalytic mechanism, protein chain length, etc. Among them, short-chain dehydrogenases, SDRs are a non-metal dependent enzyme type, usually a single subunit contains about 250 amino acid residues, and have a multimeric protein such as a monomer, a dimer or a tetramer, and SDRs are usually divided into 5 subfamilies according to the difference of coenzyme binding sites and catalytic mechanisms, and most importantly, classical and extended SDRs. The sequence similarity between SDRs, although only 15-30%, is highly conserved, higher-order structure, with the catalytic quadruplet typically being Asn (aspartic acid) -Ser (serine) -Tyr (tyrosine) -Lys (lysine). The MDRs of medium-chain dehydrogenase are zinc or non-zinc dependent enzymes, usually exist in the form of homologous polymers, and the single subunit usually contains 350 amino acid residues, and has higher sequence consistency of 40% -90% compared with the short-chain dehydrogenase. Aldehyde ketoreductase AKRs is a non-metal dependent type of dehydrogenase that typically exists in the form of a single polymer containing 320 amino acids. Although they differ greatly in three-dimensional structure from short-chain dehydrogenases, they are functionally similar. AKRs is capable of catalyzing the metabolism of various substances such as furfural, aldehyde esters, alkyl groups, polycyclic aromatic hydrocarbons and the like, so that the substrate spectrum is very wide.
The catalytic mechanism of the short-chain carbonyl reductase related to the patent is mainly as follows: as a non-metal dependent enzyme, it is firstly combined with reduced coenzyme NAD (P) H to form holoenzyme, then after the substrate enters a catalytic active center pocket, the catalytic tetrad starts to act, tyrosine and serine form hydrogen bonds with carbonyl oxygen in the substrate to firmly fix the substrate in the pocket, meanwhile, as the most conserved amino acid of reductase family, tyrosine is also responsible for providing hydrogen ions for carbonyl oxygen for subsequent catalysis, and asparagine activates lysine to form hydrogen bonds with the coenzyme to firmly stabilize the substrate in the pocket. The hydrogen ions provided by the tyrosine attack the carbonyl oxygen on the substrate, while the hydrogen ions on the coenzyme attack the carbonyl carbon on the substrate, and the two phases further reduce the carbonyl of the substrate to the corresponding chiral alcohol, so that the oxidized coenzyme which is released and oxidized is also separated from the enzyme, and the whole catalytic process is ended.
The (3R, 5S) -6-chloro-3,5-dihydroxyhexanoate (tert-butyl (3R, 5S) -6-chloro-3,5-dihydroxyhexanoate, and (3R, 5S) -CDHH) is a chiral side chain intermediate of the HMG-CoA enzyme inhibitor rosuvastatin medicine, and can be synthesized by a chemical method and a biocatalysis method. Traditional chemistry generally requires expensive noble metal catalysts, which, despite the high cost, still do not guarantee the construction of chiral centers. At present, sodium cyanide is required to carry out ring opening reaction for synthesizing (3R, 5S) -CDHH by a chemical method which is commonly adopted at home and abroad, and a catalyst diethyl methoxyborane (Methoxydiethylborane, et 2 BOMe) is also required. Chemical synthesis, while having many advantages, has some unavoidable drawbacks, primarily cyanide is a highly toxic species, and Et 2 BOMe is also a hazardous chemical that is prone to spontaneous combustion and is expensive. Therefore, the biological enzyme method with the advantages of mild reaction conditions, simple operation and the like gradually goes into the field of view of the public, has high stereoselectivity, avoids the introduction of extremely toxic substances and is environment-friendly, so that the enzyme method gradually replaces a chemical method in recent years to synthesize (3R, 5S) -CDHH. Wolber reports that alcohol dehydrogenase cloned by Lactobacillus kefi strain is expressed in recombinant escherichia coli, and can asymmetrically reduce and catalyze gram-scale (S) -6-chloro-5-hydroxy-3-carbonyl hexanoic acid tert-butyl ester (tert-butyl (S) -6-chloro-5-hydroxy-3-oxohexanoate, (S) -CHOH) to synthesize (3R, 5S) -CDHH, d.e. value reaches 99.5% after 24 hours of reaction, and total yield of product reaction reaches 72%. Pfruende reports an effective whole-cell biological asymmetric catalytic conversion process, and (3R, 5S) -CDHH is synthesized by utilizing a two-step asymmetric reduction catalysis method of lactobacillus caucasians (Lactobacillus kefi DSM 20587), and 50g/L (dry cell weight) of lactobacillus caucasians can catalyze 100mmol/L (S) -CHOH to generate 47.5mmol/L (3R, 5S) -CDHH and d.e. >99%. Xia was mutated at positions 126, 129 and 194 using a carbonyl reductase from Candida theai (CANDIDA THEAE) to achieve 96% conversion at substrate concentrations up to 1mol/L (or 220 g/L) and a product e.e. value higher than 99% (CN 116814572A). Ni makes mutation at 45, 141 and 195 by utilizing carbonyl reductase NaKRED from Novosphingobium aromaticivorans, so that the concentration of the catalytic substrate can reach more than 100g/L, and the catalyst has stereoselectivity as high as 99.5%, high enzyme activity and good catalytic efficiency (CN 116676285A).
Likewise, the chiral intermediate 6-cyano- (3R, 5R) -dihydroxyhexanoate of the HMG-CoA enzyme inhibitor atorvastatin can be synthesized by a biocatalysis method. The Luo team successfully obtained the key intermediate, i.e., the tertiary butyl 6-cyano- (3R, 5R) -dihydroxyhexanoate with specific stereostructure by using aldehyde ketone reductase KlAKR and efficiently reducing the tertiary butyl (R) -6-cyano-5-hydroxy-3-carbonyl hexanoate with the concentration of 450g/L substrate, and the d.e. selectivity is more than 99.5 percent, and the space-time yield reaches 1.24 kg/(L.d). Wang reduced (R) -6-cyano-5-hydroxy-3-carbonyl hexanoic acid tert-butyl ester with carbonyl reductase from STARMERELLA MAGNOLIA, e.e. 98% or more, conversion 95% or more (CN 116515780A).
Therefore, the research on the biocatalysis process of the (3R, 5S) -CDHH or the 6-cyano- (3R, 5R) -dihydroxyhexanoate has important significance, not only can provide a new route for the synthesis of the (3R, 5S) -CDHH or the 6-cyano- (3R, 5R) -dihydroxyhexanoate, but also can provide an enzyme source with high stereoselectivity and high catalytic activity for the (3R, 5S) -CDHH or the 6-cyano- (3R, 5R) -dihydroxyhexanoate.
Disclosure of Invention
In order to further improve the production efficiency and the product purity of statin intermediate chiral alcohol (3R, 5S) -CDHH or 6-cyano- (3R, 5R) -dihydroxyhexanoate, the invention carries out intensive research on Rhodosporidium toruloides ZJB 2014212-derived stereospecific recombinant carbonyl reductase SCR, and obtains a recombinant carbonyl reductase mutant SCR-Asp25Thr with high activity and high stereoselectivity, and a coding gene thereof, a recombinant vector containing the mutant coding gene and genetic engineering bacteria. The recombinant carbonyl reductase mutant is applied to the biological enzyme method for synthesizing chiral alcohol, the yield of the product (3R, 5S) -CDHH is more than 92%, e.e. is more than 99%, and the yield of the product 6-cyano- (3R, 5R) -dihydroxyhexanoate tert-butyl ester reaches 97.1%, e.e. is more than 99%.
The invention provides a recombinant carbonyl reductase mutant, which is obtained by carrying out mutation on the 25 th site of an amino acid sequence of Rhodosporidium toruloides ZJB 2014212-derived recombinant carbonyl reductase. The amino acid sequence of the Rhodosporidium toruloides ZJB 2014212-derived recombinant carbonyl reductase is shown as SEQ ID NO. 2.
Preferably, the mutation is an aspartic acid mutation threonine at position 25.
The invention also provides a gene encoding the recombinant carbonyl reductase mutant. Preferably, the acylase mutant is obtained by mutating a codon encoding aspartic acid at position 25 into a codon encoding threonine on the basis of a recombinant carbonyl reductase SCR having a base sequence shown in SEQ ID NO. 1. As known in the art, an allelic variant is an alternative form of a polynucleotide, which may be a substitution, deletion, or insertion of a polynucleotide, without substantially altering the function of the peptide protein it encodes.
The invention also provides a recombinant vector of the recombinant carbonyl reductase mutant coding gene. The recombinant vector comprises a polynucleotide operably linked to control sequences suitable for directing expression in a host cell. Various vectors conventional in the art, such as various plasmids, phage or viral vectors, etc., are linked to the recombinant carbonyl reductase mutant nucleotide sequences of the present invention and are intended to fall within the scope of the present invention. The recombinant vector preferably uses a plasmid pET-28b as an expression vector, and the coding gene of the novel carbonyl reductase mutant is connected to the plasmid pET-28b.
The invention also provides a genetic engineering bacterium of the recombinant carbonyl reductase mutant coding gene. Introducing exogenous recombinant carbonyl reductase mutant coding genes into host cells through a genetic engineering technology to construct genetically engineered bacteria and express the genetically engineered bacteria so as to obtain the novel carbonyl reductase mutant; wherein the host cell may be a bacterial, fungal, plant cell or animal cell, preferably E.coli ESCHERICHIA COLI BL (DE 3) as an expression host.
The invention also provides application of the recombinant carbonyl reductase mutant, the recombinant vector or the genetically engineered bacterium in preparing chiral alcohol by biological catalysis. Preferably, the application is: the method comprises the steps of using wet thalli or enzyme liquid extracted after ultrasonic disruption of the wet thalli obtained by fermenting and culturing genetic engineering bacteria containing recombinant carbonyl reductase mutant encoding genes as a catalyst, using precursor ketone as a substrate, using isopropanol as an auxiliary substrate, using NAD (P) H as a coenzyme, preferably forming a reaction system in a buffer solution with pH value of 6-8, and obtaining chiral alcohol through asymmetric reduction reaction under the conditions of 25-35 ℃ and 200-800 rpm. It will be appreciated that there are a number of possible format choices when reference is made to the use of the recombinant carbonyl reductase mutants of the present invention. This includes the following forms: the whole cell form of the genetically engineered bacterium is used, the crude enzyme form without purification is used, and the partially or completely purified enzyme form is used. In addition, the acylase mutant of the invention can be prepared into immobilized enzyme or immobilized cell form biocatalyst by utilizing the known enzyme immobilization technology, thereby further improving the stability and reusability of the enzyme and being beneficial to the application thereof in the fields of industrial production and the like.
Preferably, the precursor ketone is selected from (S) -tert-butyl 6-chloro-5-hydroxy-3-carbonyl hexanoate or 6-cyano- (5R) -3-carbonyl hexanoate. The substrate (S) -tert-butyl 6-chloro-5-hydroxy-3-carbonyl hexanoate ((S) -CHOH) is asymmetrically reduced to (3R, 5S) -CDHH under the catalysis of recombinant carbonyl reductase mutant. Substrate tert-butyl 6-cyano- (5R) -3-carbonyl hexanoate asymmetrically reduces tert-butyl 6-cyano- (3R, 5R) -dihydroxyhexanoate under the catalysis of recombinant carbonyl reductase mutant
Preferably, the catalyst is used in the reaction system in an amount of 3-50g/L buffer based on the weight of wet bacteria.
Preferably, the initial final concentration of the precursor ketone in the reaction system is 200-500g/L.
Preferably, the final concentration of isopropanol volume in the reaction system is 10% -70%, preferably 20% -50%, more preferably 40%. Referring to FIG. 1, the coenzyme NAD (P) H regeneration system of the recombinant carbonyl reductase and the mutant thereof is preferably a single-enzyme double-substrate coupling system, and the isopropanol is selected as an auxiliary substrate of the coenzyme regeneration system, so that the production cost can be effectively saved. Further, the inventor team optimizes the concentration of isopropanol in the coenzyme cycle regeneration system, and the result shows that when the volume concentration of isopropanol is 40%, the coenzyme cycle can basically meet the requirement of carbonyl reductase on NADPH, and the catalytic reaction product e.e. >99%.
The invention has the beneficial effects that: compared with wild enzyme, the recombinant carbonyl reductase mutant provided by the invention has high activity and high stereoselectivity, and further improves the catalytic efficiency on substrate precursor ketone. The recombinant carbonyl reductase mutant is applied to the synthesis of chiral alcohol by a biological enzyme method, and the yield of the product (3R, 5S) -CDHH after catalysis for 6 hours is more than 92% and e.e. is more than 99% when the substrate concentration is 400 g/L; the yield of the product tert-butyl 6-cyano- (3R, 5R) -dihydroxyhexanoate after 3h catalysis reached 97.1%, e.e. >99% at a substrate concentration of 200 g/L. In addition, in the reaction system for preparing chiral alcohol by catalysis, a single-enzyme double-substrate coupling system is constructed, isopropanol is selected as an auxiliary substrate of a coenzyme regeneration system, so that the production cost can be effectively saved, and the method has important significance for industrial application of preparing chiral alcohol by catalysis of a biological enzyme method. Compared with the chemical method for preparing chiral alcohol, the method utilizes the recombinant carbonyl reductase mutant to asymmetrically catalyze and reduce the precursor ketone to synthesize the chiral alcohol, simplifies the chemical catalysis step, has milder reaction conditions, has low requirements on equipment, reduces the reaction cost and is environment-friendly.
Drawings
FIG. 1 is a schematic diagram of the synthesis of chiral alcohols (3R, 5S) -CDHH using asymmetric catalytic reduction of precursor ketones with recombinant carbonyl reductase mutants according to the invention.
Detailed Description
The following specific examples are presented to illustrate the present invention, and those skilled in the art will readily appreciate the additional advantages and capabilities of the present invention as disclosed herein. The invention may be practiced or carried out in other embodiments that depart from the specific details, and the details of the present description may be modified or varied from the spirit and scope of the present invention. It should be noted that the following embodiments and features in the embodiments may be combined with each other without conflict. The methods used in the examples of the present invention are conventional methods, and the reagents used are commercially available.
Liquid phase detection method
High performance liquid chromatography instrument: shimadzu LC-20AD system-SPD-20A ultraviolet detector
The conversion was measured using a chromatographic column: agilent Zorbax SB-C8 column (150X4.6mm, 5 μm), mobile phase composed of acetonitrile water solution with volume ratio of 3:7 (v/v), flow rate of 1mL/min, detection wavelength of 210nm, sample injection amount of 10 μm, column temperature box of 40 deg.C, (S) -CHOH, (3R, 5S) -CDHH retention time of 8.348min and 5.534min respectively; when detecting e.e.: chiral column OD-H column (250×4.6mm,5 μm) was used, mobile phase: n-hexane: isopropanol=85: the retention times of the tert-butyl (S) -CHOH, (3R, 5S) -CDHH, (3S, 5S) -6-chlorodihydroxyhexanoate were 5.99min,5.09min and 4.93min, respectively, at a flow rate of 1mL/min at a detection wavelength of 215 nm.
The chromatographic column J & K SCIENTIFIC C18 reversed phase column (4.6mm.times.150mm, 5 um) was used, the mobile phase consisted of acetonitrile aqueous solution with volume ratio of 1:3 (v/v), the flow rate was 1mL/min, the detection wavelength was set to 210nm, the sample injection amount was 10 μm, the column oven was set to 40 ℃, the retention time of tert-butyl 6-cyano- (5R) -3-carbonyl hexanoate was about 15.353min, the retention time of tert-butyl 6-cyano- (3R, 5R) -dihydroxyhexanoate was about 9.057min (S-configuration) and 9.501min (R-configuration).
Example 1: obtaining recombinant carbonyl reductase mutants
Recombinant bacteria E.coli BL21 (DE 3) pET28b-SCR containing recombinant carbonyl reductase SCR coding gene expression vector pET28b-SCR is used as an initial strain, and site-directed saturation mutation and site-directed mutation are respectively carried out so as to further improve the catalytic activity and substrate tolerance of carbonyl reductase to substrate precursor ketone.
The mutant primers are shown in Table 1, with the mutation sites underlined. The mutation was introduced by PCR using plasmid DNA containing the SCR gene as a template, and the PCR reaction procedure was as follows: 98 ℃ for 3min; 26 cycles are repeated at 98℃for 10s,55℃for 5s and 72℃for 6min for 30 s; the extension was continued for 10min at 72 ℃. The PCR product was treated with DpnI at 37℃for 3 hours, inactivated and transformed into E.coli BL21 (DE 3) recipient bacteria, which were plated on LB solid plates containing a final concentration of 50mg/L of kana resistance, and incubated at 37℃for 12 hours. Single colony is randomly picked for sequencing analysis, and different mutant amino acids at different mutation points are obtained.
TABLE 1 mutant primers
A series of different amino acid mutants were obtained by site-directed saturation mutagenesis. The correct clone of sequencing analysis is inoculated into LB liquid medium containing 50 mug/mL kanamycin resistance of final concentration, cultured for 8 hours at 37 ℃, inoculated into fresh LB liquid medium containing 50 mug/mL kanamycin resistance of final concentration at 1 percent of inoculum size (v/v), cultured until the cell OD600 reaches 0.6-0.8 at 37 ℃ and 180rpm, added with IPTG of final concentration of 0.1mM, induced and cultured for 12 hours at 28 ℃, centrifuged for 10 minutes at 4 ℃ and 8000rpm, the supernatant is discarded, and the precipitate is collected, thus obtaining the recombinant escherichia coli wet cell containing recombinant carbonyl reductase mutant gene. The conversion reaction was carried out in a 10mL conversion bottle with a substrate ((S) -CHOH) concentration of 100g/L, isopropyl alcohol of 4mL, wet cell of the mutant of 15g/L, magnetic stirring at 30℃and 600rpm for 20min, and the reaction solution was analyzed by HPLC to determine the relative enzyme activity of the mutant and screen mutants having relatively high catalytic activity, and the results are shown in Table 2.
TABLE 2 relative enzyme activities of recombinant carbonyl reductase mutants
Carbonyl reductase type | Relative enzyme Activity (%) |
SCR | 100±1.43 |
SCR-Asp25Thr | 115.93±1.33 |
SCR-Lys211Ile | 108.46±1.21 |
SCR-Val181Ile | 102.31±1.32 |
The result shows that the optimal mutant obtained by the site-directed saturation mutation and the site-directed mutation method is SCR-Asp25Thr, namely, the optimal mutant is obtained by mutation of threonine by aspartic acid mutation at the 25th site of recombinant carbonyl reductase with the amino acid sequence shown as SEQ ID NO. 2.
Example 2: preparation of recombinant carbonyl reductase mutant wet thalli
The recombinant E.coli BL21 (DE 3)/pET 28b-SCR-Asp25Thr gene containing recombinant carbonyl reductase mutant SCR-Asp25Thr gene obtained in example 1 was inoculated into LB liquid medium containing kanamycin resistance at a final concentration of 50. Mu.g/mL, cultured at 37℃and 180rpm for 8 hours, then inoculated into fresh LB liquid medium containing kanamycin resistance at a final concentration of 50. Mu.g/mL at 1% inoculum size (v/v), cultured at 37℃and 180rpm until the cell OD600 reached 0.6-0.8, IPTG at a final concentration of 0.1mM was added, after 12 hours of induction culture at 28℃and at 4℃and 8000rpm, the supernatant was discarded, and the precipitate was collected to obtain recombinant E.coli wet cell containing recombinant carbonyl reductase mutant gene. The wet cell can be directly used as a biocatalyst or used for protein purification. E.coli BL21 (DE 3)/pET 28b-SCR wet cells containing the gene expressing recombinant carbonyl reductase were prepared in the same manner.
Example 3: isolation and purification of carbonyl reductase mutants
The wet cells obtained in example 2 were washed three times with physiological saline, and resuspended in 1g of wet cells in 20mL of 20mM potassium phosphate buffer pH7.0, and sonicated (60W, for 1s, intermittently for 1s, continuously for 30 min) under ice bath conditions to obtain a cell disruption solution. And centrifuging the cell disruption solution obtained after ultrasonic disruption at 8000rpm and at 4 ℃ for 25min to obtain a supernatant which is the required crude enzyme solution, and determining the supernatant as the crude enzyme solution I.
Ammonium sulfate fractional salting out: the most common salt used in salting-out is (NH4)2SO4、Na2SO4、MgSO4.(NH4)2SO4, which is a salt most commonly used in salting-out step, because of its high solubility and small temperature coefficient, and its good separation effect, generally does not denature proteins, and is available at low cost. The protein can be dehydrated under the influence of high-concentration neutral salt, so that the charge is neutralized, the colloid stability of the protein is destroyed and separated out, and meanwhile, the salting-out effect of the protein is a reversible process and can be redissolved when diluted by water or buffer solution. Thus, as the saturation of ammonium sulfate increases, the protein content in the supernatant gradually decreases; conversely, the amount of protein precipitated in the precipitate increases gradually. The method is to add 5mL of crude enzyme solution in 8 small beakers numbered 1-8. 0.57g, 0.88g, 1.215g, 1.565g, 1.95g, 2.36g, 2.805g and 3.31g of ground ammonium sulfate are added respectively, so that the saturation of the ammonium sulfate in the crude enzyme solution reaches 20%, 30%, 40%, 50%, 60%, 70%, 80% and 90% respectively. Ammonium sulfate is slowly added, stirred on ice to dissolve, and kept stand for 4 hours in a refrigerator at 4 ℃ after stirring. The liquid in the beaker was taken out and centrifuged (8000 rpm,25 min), and the supernatant was weighed to calculate the supernatant volume and the enzyme activity and protein content were measured. The two saturations with the highest specific activity and the highest protein precipitation rate can be found out through calculation to obtain an ammonium sulfate fractional salting-out specific activity chart and an ammonium sulfate fractional salting-out protein precipitation rate chart, namely the optimal precipitation saturation of the hybrid protein and the optimal precipitation saturation of the target protein, so that a large amount of hybrid protein can be removed; ammonium sulfate is graded and salted out, the crude enzyme solution I is continuously stirred in an ice-water bath after cells are broken by ultrasonic, ammonium sulfate is slowly added to reach the final concentration of 50 percent of saturation degree, and the mixture is kept stand for 4 hours in a refrigerator at the temperature of 4 ℃. Centrifugation was performed at 8000rpm for 25min, the precipitate was discarded, and the supernatant was further added with ammonium sulfate to a final concentration of 70% saturation, and allowed to stand in a refrigerator at 4℃for 4 hours. Again, centrifugation was performed at 8000rpm for 25min, the supernatant was discarded, and the pellet was reconstituted with an appropriate amount of 20mM potassium phosphate buffer, pH 7.0. The crude enzyme solution II was obtained by dialysis against potassium phosphate buffer at pH 7.0 at 20mM overnight at 4 ℃.
DEAE Sepharose Fast Flow anion exchange chromatography: ion exchange chromatography is a method of separation using reversible ion exchange that occurs between stationary phase coupled ion exchange groups and mobile phase dissociated ionic compounds. Anion exchange chromatography is used in the primary chromatographic purification of most oxidoreductases. DEAE Sepharose Fast Flow anion exchange columns (1.6cm.times.20 cm) were first equilibrated with 20mM, pH 7.0, pB potassium phosphate buffer at a flow rate of 1.5mL/min, and after the baseline was leveled off, the dialyzed crude enzyme solution II was loaded onto the column at a loading flow rate of 1.0mL/min. After loading, the sample is eluted with 20mM potassium phosphate buffer with pH 7.0 at a flow rate of 1.5mL/min, and after the baseline is leveled, the sample is eluted with a gradient of 0-0.8M NaCl. Collecting active part, concentrating to obtain pure enzyme. The whole purification process was operated at 4 ℃. And (3) determining the protein content of the trapped fluid by adopting a BCA kit method, and freezing the trapped fluid in a refrigerator at the temperature of minus 80 ℃ to obtain recombinant carbonyl reductase SCR and mutant SCR-Asp25Thr pure enzyme thereof.
Example 4: recombinant carbonyl reductase and mutant enzyme activity thereof
The carbonyl reductase SCR and its mutant SCR-Asp25Thr pure enzyme obtained in example 3 were used to catalyze the substrate (S) -CHOH to synthesize (3R, 5S) -CDHH.
The composition of the enzyme activity catalytic system and the catalytic conditions are as follows: to 5mL of 100mM phosphate buffer solution at pH 7.0, carbonyl reductase mutant pure enzyme diluted to the same concentration with the same buffer solution (final concentration of SCR 2.5. Mu.g/mL, SCR-Asp25Thr 2.5. Mu.g/mL), (S) -CHOH final concentration of 10mM, coenzyme NAD (P) H final concentration of 2mM, pre-heated at 30℃for 3min at 600rpm, and reacted for 3min. The reaction was terminated by adding 5mL of 30% acetonitrile aqueous solution by volume, and after mixing uniformly, the sample was taken to detect the enzyme activity, and the results are shown in Table 3.
TABLE 3 recombinant carbonyl reductase and its mutant relative enzyme activities
Carbonyl reductase type | Relative enzyme Activity (%) | Ee value (%) |
SCR | 100±1.12 | 99 |
SCR-Asp25Thr | 116.36±1.26 | 99 |
Note that: the enzyme activity unit (U) is defined as: the amount of enzyme required to produce 1. Mu. Mol of product (3R, 5S) -CDHH in 1min at 30℃and pH 7.0 was defined as 1U. The amount of product formed was determined by HPLC detection.
Example 5: optimization of isopropanol concentration in recombinant carbonyl reductase coenzyme regeneration system
Referring to FIG. 1, the coenzyme NAD (P) H regeneration system of the recombinant carbonyl reductase and the mutant thereof is preferably a single-enzyme double-substrate coupling system, and the isopropanol is selected as an auxiliary substrate of the coenzyme regeneration system, so that the production cost can be effectively saved.
The wet cell E.coli BL21 (DE 3)/pET 28b-SCR-Asp25Thr was obtained as in example 2 and used as biocatalyst to synthesize (3R, 5S) -CDHH using (S) -CHOH as substrate.
Conversion system composition and catalytic conditions: 10mL of potassium phosphate buffer (100 mM, pH 7.0), 10%, 20%, 30%, 40%, 50%, 60% and 70% of the final concentration of the recombinant carbonyl reductase mutant mut-Asp25Thr wet cell (15 g/L buffer) in 100g/L buffer and isopropyl alcohol. The reaction was carried out in a magnetic stirring water bath at 30℃and 600rpm for 20min. After the completion of the reaction, the reaction was terminated by adding 1mL of acetonitrile, the reaction mixture was thoroughly mixed, and an appropriate amount of the reaction mixture was measured for conversion by HPLC, and the results are shown in Table 4.
TABLE 4 optimization of isopropyl alcohol concentration
Final volume concentration of isopropanol | Conversion rate |
10% | 37.22% |
20% | 51.45% |
30% | 52.33% |
40% | 66.72% |
50% | 48.79% |
60% | 38.16% |
70% | 33.29% |
The results show that at an isopropanol volume concentration of 40%, the coenzyme cycle has been substantially able to meet the NADPH requirement of the carbonyl reductase, catalyzing the reaction product e.e. >99% above.
Application of recombinant carbonyl reductase mutant in preparation of (3R, 5S) -CDHH
Example 6:
The E.coli BL21 (DE 3)/pET 28b-SCR-Asp25Thr wet cell containing the expression recombinant plasmid obtained in example 2 is used as a biocatalyst, and (S) -CHOH is used as a substrate to carry out bioconversion reaction to prepare (3R, 5S) -CDHH.
The composition of the 10mL catalyst system and the catalyst conditions are as follows: in a 10mL reaction system, 6mL of potassium phosphate buffer solution (pH 7.0) is added, recombinant carbonyl reductase mutant SCR-Asp25Thr wet thalli (the dosage is 50g/L buffer solution) is added, 4mL of isopropanol is added, the initial substrate final concentration is 400g/L, a water bath is carried out at 30 ℃, the magnetic stirring device is at 600rpm, the reaction is sampled at regular time, the sampling volume is 100 mu L, 50 times of dilution is carried out by using 30% acetonitrile water solution by volume concentration, and the conversion rate is determined by HPLC analysis. The results showed that the yield of the product (3R, 5S) -CDHH after 8h of catalysis reached 97.3%, e.e. >99% at a substrate concentration of 400g/L in 10mL of catalytic system.
Example 7:
The E.coli BL21 (DE 3)/pET 28b-SCR-Asp25Thr wet cell containing the expression recombinant plasmid obtained in example 2 is used as a biocatalyst, and (S) -CHOH is used as a substrate to carry out bioconversion reaction to prepare (3R, 5S) -CDHH.
100ML of the catalytic system consists of the following components and catalytic conditions: in a 100mL reaction system, 60mL of a potassium phosphate buffer solution (pH 7.0) was added, a recombinant carbonyl reductase mutant mut-Asp25Thr wet cell (50 g/L buffer solution was used), 40mL of isopropyl alcohol was added, the initial substrate final concentration was 400g/L, a water bath was carried out at 30℃and the magnetic stirring apparatus was set at 1200rpm, the reaction was sampled at regular time, the sampling volume was 100. Mu.L, and 50-fold dilution was carried out with a 30% acetonitrile aqueous solution by volume concentration, and the conversion was determined by HPLC analysis. The results show that the yield of the product (3R, 5S) -CDHH after 6h of catalysis reaches 96.4%, e.e. >99% at a substrate concentration of 400g/L in 100mL of the catalytic system.
Example 8:
The E.coli BL21 (DE 3)/pET 28b-SCR-Asp25Thr wet cell containing the expression recombinant plasmid obtained in example 2 is used as a biocatalyst, and (S) -CHOH is used as a substrate to carry out bioconversion reaction to prepare (3R, 5S) -CDHH.
The difference compared to example 6 is that the initial substrate concentration is 500g/L, the remainder being identical. The results showed that the yield of the product (3R, 5S) -CDHH reached 92.1%, e.e. >99% after 6h of catalysis at a substrate concentration of 500g/L in 10mL of the catalytic system.
Application of recombinant carbonyl reductase in preparation of (3R, 5S) -CDHH
Comparative example 1:
Compared with example 6, the difference is that the E.coli BL21 (DE 3)/pET 28b-SCR wet cell containing the expression recombinant plasmid obtained in example 2 is used as a biocatalyst, and (S) -CHOH is used as a substrate for biological conversion reaction to prepare (3R, 5S) -CDHH, and the rest are the same. The results showed that the yield of the product (3R, 5S) -CDHH reached 94.1%, e.e. >99% after 6h of catalysis at a substrate concentration of 400g/L in 10mL of the catalytic system.
Comparative example 2:
Compared with example 8, the difference is that the E.coli BL21 (DE 3)/pET 28b-SCR wet cell containing the expression recombinant plasmid obtained in example 2 is used as a biocatalyst, and (S) -CHOH is used as a substrate for biological conversion reaction to prepare (3R, 5S) -CDHH, and the rest are the same. The results show that the yield of the product (3R, 5S) -CDHH after 6h of catalysis reaches 89.4%, e.e. >99% at a substrate concentration of 500g/L in 10mL of the catalytic system.
Application of recombinant carbonyl reductase mutant in preparation of tert-butyl 6-cyano- (3R, 5R) -dihydroxyhexanoate
The E.coli BL21 (DE 3)/pET 28b-SCR-Asp25Thr wet cell containing the expression recombinant plasmid obtained in example 2 is used as a biocatalyst, and 6-cyano- (5R) -3-carbonyl tert-butyl caproate is used as a substrate for biological conversion reaction to prepare 6-cyano- (3R, 5R) -dihydroxyhexanoate tert-butyl ester.
The catalytic system comprises the following components and catalytic conditions: in a 10mL reaction system, 6mL of potassium phosphate buffer solution (pH 7.0) is added, recombinant carbonyl reductase mutant SCR-Asp25Thr wet thalli (the dosage is 50g/L buffer solution) is added, 4mL of isopropanol is added, the initial substrate final concentration is 200g/L, a water bath is carried out at 30 ℃, the magnetic stirring device is at 600rpm, the reaction is sampled at regular time, the sampling volume is 100 mu L, 50 times of dilution is carried out by using 30% acetonitrile water solution by volume concentration, and the conversion rate is determined by HPLC analysis. The results show that the yield of the product tert-butyl 6-cyano- (3R, 5R) -dihydroxyhexanoate reaches 97.1%, e.e. >99% after 3h of catalysis at a substrate concentration of 200 g/L.
The above examples are merely illustrative of the preferred embodiments of the present invention and are not intended to limit the scope of the present invention, and various modifications and improvements made by those skilled in the art to the technical solution of the present invention should fall within the protection scope of the present invention without departing from the design spirit of the present invention.
Claims (10)
1. A recombinant carbonyl reductase mutant is obtained by mutating the 25 th position of an amino acid sequence of Rhodosporidium toruloides ZJB 2014212-derived recombinant carbonyl reductase.
2. The recombinant carbonyl reductase mutant of claim 1, wherein the mutation is an aspartic acid mutant threonine at position 25.
3. A gene encoding the recombinant carbonyl reductase mutant of claim 1 or 2.
4. A recombinant vector comprising the gene encoding the recombinant carbonyl reductase mutant of claim 3.
5. A genetically engineered bacterium comprising a gene encoding the recombinant carbonyl reductase mutant of claim 3.
6. The use of the recombinant carbonyl reductase mutant of claim 1 or 2, the recombinant vector of claim 4, or the genetically engineered bacterium of claim 5 in biocatalysis for preparing chiral alcohols.
7. The application of claim 6, wherein the application is: the method comprises the steps of using wet thalli or enzyme liquid extracted after ultrasonic crushing of wet thalli obtained by fermenting and culturing genetic engineering bacteria containing recombinant carbonyl reductase mutant encoding genes as a catalyst, using precursor ketone as a substrate, using isopropanol as an auxiliary substrate to form a reaction system, and obtaining chiral alcohol through asymmetric reduction reaction.
8. Use according to claim 8, wherein the precursor ketone is selected from (S) -tert-butyl 6-chloro-5-hydroxy-3-carbonyl hexanoate or tert-butyl 6-cyano- (5R) -3-carbonyl hexanoate.
9. The use according to claim 8, wherein the initial final concentration of precursor ketone in the reaction system is 200-500g/L.
10. The use according to claim 8, wherein the final concentration of isopropanol volume in the reaction system is between 10% and 70%.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410092889.4A CN117904066A (en) | 2024-01-23 | 2024-01-23 | Recombinant carbonyl reductase mutant and application thereof in catalytic synthesis of chiral alcohol |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410092889.4A CN117904066A (en) | 2024-01-23 | 2024-01-23 | Recombinant carbonyl reductase mutant and application thereof in catalytic synthesis of chiral alcohol |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117904066A true CN117904066A (en) | 2024-04-19 |
Family
ID=90690590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410092889.4A Pending CN117904066A (en) | 2024-01-23 | 2024-01-23 | Recombinant carbonyl reductase mutant and application thereof in catalytic synthesis of chiral alcohol |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117904066A (en) |
-
2024
- 2024-01-23 CN CN202410092889.4A patent/CN117904066A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107058251B (en) | Recombinant carbonyl reductase mutant, gene, vector, engineering bacterium and application thereof | |
CN107586763B (en) | Carbonyl reductase mutant, vector, engineering bacterium and application thereof | |
CN110573605B (en) | Slow rhizobium monooxygenase and application thereof in preparation of chiral sulfoxide | |
CN108728421B (en) | Carbonyl reductase mutant and application thereof | |
JPWO2007142210A1 (en) | Method for producing optically active alcohol | |
CN109468291B (en) | Carbonyl reductase EbSDR8 mutant and construction method and application thereof | |
WO2016138641A1 (en) | Generation and use of candida and carbonyl reductase thereof | |
CN109055324B (en) | Improved ketoreductase and application thereof | |
CN112662638A (en) | Function of novel R-selective styrene monooxygenase | |
CN110387359B (en) | Carbonyl reductase mutant and application thereof | |
CN108486075B (en) | Recombinant carbonyl reductase mutant, gene, engineering bacterium and application thereof | |
CN108410831B (en) | Ketoacid reductase, gene, engineering bacterium and application in synthesis of chiral aromatic 2-hydroxy acid | |
CN113817693B (en) | Short-chain carbonyl reductase PpYSDR mutant, encoding gene, recombinant expression vector, genetic engineering bacterium and application | |
CN113652407B (en) | Carbonyl reductase mutant and application thereof in asymmetric synthesis of chiral compound | |
CN115927488A (en) | Application of oxidoreductase and mutant thereof in biosynthesis of nootkatone | |
WO2009070822A2 (en) | Recombinant pichia pastoris cell | |
CN113322291A (en) | Synthesis method of chiral amino alcohol compound | |
CN113444702B (en) | Enone reductase mutant and application thereof | |
CN113930457B (en) | Method for synthesizing (S) -citronellol by double enzyme coupling | |
CN117904066A (en) | Recombinant carbonyl reductase mutant and application thereof in catalytic synthesis of chiral alcohol | |
CN113151131B (en) | Self-induction culture medium for producing isoeugenol monooxygenase and application thereof | |
CN114410599B (en) | Carbonyl reductase mutant and application thereof in preparation of rosuvastatin chiral intermediate | |
CN116790569B (en) | Pyruvic acid decarboxylase mutant and application thereof in preparation of alpha-hydroxyketone compound | |
CN113025546B (en) | Method for producing tyrosol by converting L-tyrosine through multienzyme cascade | |
CN113388627B (en) | Reductase LX05 gene, genetic engineering bacterium containing gene and application of gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |